What is Pharmacyte Biotech Inc's earnings per share (EPS)?

Pharmacyte Biotech Inc (PMCB) reported diluted earnings per share of -$2.77 for fiscal year 2026. This represents a -186.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pharmacyte Biotech Inc Financials

PMCB

FY2026 annual

Revenue $0 YoY not available

Net Income -$19.4M -163.4% YoY

EPS (Diluted) -$2.77 -186.8% YoY

Free Cash Flow Not reported for FY2026

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Apr 30, 2026 Reported Jul 29, 2026 Currency USD FYE April

Pharmacyte Biotech Inc (PMCB) reported $0 in revenue for fiscal year 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PMCB FY2026 2026-08-15

Cash-funded development is the dominant mechanic: operating losses consume liquidity while financing activity periodically replenishes it.

FY2025’s reported profit of $30.7M coexisted with an operating loss of -$4.4M, while operating cash flow remained negative at -$3.0M. That disconnect indicates the profit was driven by items outside ongoing operations rather than by cash-generating activity; FY2026 returned to a net loss of -$19.4M.

Cash declined from $85.4M in FY2022 to $18.6M in FY2026, while the latest year consumed $5.2M through operations. The pattern points to a development-stage model whose liquidity depends on funding decisions rather than operating receipts.

The latest liquidity cushion remains unusually large relative to near-term obligations, with a current ratio of 45.3x and current liabilities of $826K. However, FY2026 financing provided $6.6M while operations consumed $5.2M, showing that external funding was needed to offset the core cash shortfall.

Financial Health Signals

Financial health score not available

Pharmacyte Biotech Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-2.39

Pharmacyte Biotech Inc scores -2.39, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.5M) relative to total liabilities ($11.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Pharmacyte Biotech Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Pharmacyte Biotech Inc reported a net loss of $19.4M while operations used $5.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Pharmacyte Biotech Inc generated $0 in revenue in fiscal year 2026.

Net Income

-$19.4M

YoY-163.4%

Pharmacyte Biotech Inc reported -$19.4M in net income in fiscal year 2026. This represents a decrease of 163.4% from the prior year.

EPS (Diluted)

-$2.77

YoY-186.8%

Pharmacyte Biotech Inc earned -$2.77 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 186.8% from the prior year.

EBITDA

Not reported for fiscal year 2026.

Cash & Balance Sheet

Cash & Debt

$18.6M

YoY+22.6%

5Y CAGR+53.2%

10Y CAGR+25.5%

Pharmacyte Biotech Inc held $18.6M in cash as of fiscal year 2026; long-term debt is not reported for that period.

Shares Outstanding

11M

YoY+58.0%

Pharmacyte Biotech Inc had 11M shares outstanding in fiscal year 2026. This represents an increase of 58.0% from the prior year.

Free Cash Flow

Not reported for fiscal year 2026.

Dividends Per Share

Not reported for fiscal year 2026.

Margins & Returns

Return on Equity

-58.3%

YoY-117.4pp

5Y CAGR-5.2pp

10Y CAGR+34.6pp

Pharmacyte Biotech Inc's ROE was -58.3% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 117.4 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2026.

Operating Margin

Not reported for fiscal year 2026.

Net Margin

Not reported for fiscal year 2026.

Capital Allocation

R&D Spending

$391K

YoY-10.7%

5Y CAGR-15.6%

10Y CAGR-12.0%

Pharmacyte Biotech Inc invested $391K in research and development in fiscal year 2026. This represents a decrease of 10.7% from the prior year.

Share Buybacks

$402K

YoY-84.2%

Pharmacyte Biotech Inc spent $402K on share buybacks in fiscal year 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 84.2% from the prior year.

Capital Expenditures

Not reported for fiscal year 2026.

PMCB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

PMCB quarterly income statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$12K-81.7%	$67K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0-100.0%	$10K-50.4%	$19K
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0-100.0%	$3K-94.6%	$47K
R&D Expenses	$391K-10.7%	$438K+7.6%	$407K-13.0%	$469K-32.2%	$691K-24.6%	$916K+204.2%	$301K-34.5%	$460K-77.0%	$2.0M+69.0%	$1.2M-16.0%	$1.4M-59.5%	$3.5M+974.8%	$324K	$0	N/A
SG&A Expenses	$4.9M+24.7%	$3.9M-35.6%	$6.1M+449.4%	$1.1M+2.0%	$1.1M+160.8%	$418K-64.0%	$1.2M-15.7%	$1.4M-24.2%	$1.8M+144.2%	$745K-67.5%	$2.3M+6.0%	$2.2M+12.7%	$1.9M+210.7%	$617K+48.3%	$416K
Operating Income	-$6.9M-56.6%	-$4.4M+48.6%	-$8.5M-32.0%	-$6.5M-47.0%	-$4.4M-21.2%	-$3.6M+5.3%	-$3.8M+6.7%	-$4.1M+41.3%	-$7.0M-57.2%	-$4.4M+26.9%	-$6.1M+54.2%	-$13.3M+30.1%	-$19.0M-1026.8%	-$1.7M+13.6%	-$1.9M
Interest Expense	N/A	N/A	N/A	$0-100.0%	$509-83.3%	$3K+572.4%	$453	$0	$0-100.0%	$2K+29.2%	$1K-75.9%	$5K-75.3%	$20K-87.1%	$154K-32.9%	$230K
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	-$19.4M-163.4%	$30.7M+9085.0%	$334K+107.7%	-$4.3M-1.8%	-$4.2M-19.4%	-$3.6M+7.2%	-$3.8M+5.9%	-$4.1M+40.4%	-$6.8M-53.7%	-$4.4M+26.7%	-$6.1M+38.9%	-$9.9M+63.6%	-$27.3M-1605.4%	-$1.6M+15.9%	-$1.9M
EPS (Diluted)	-$2.77-186.8%	$3.19+277.2%	-$1.80-718.2%	-$0.22	-$0.27	-$2.45	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Revenue	N/A	$0	$0	$0	N/A	$0	$0	$0
R&D Expenses	N/A	$93K-34.0%	$141K+48.3%	$95K	N/A	$118K+21.3%	$97K+1.5%	$96K
SG&A Expenses	N/A	$2.0M+64.0%	$1.2M+64.0%	$753K	N/A	$842K-16.5%	$1.0M-14.0%	$1.2M
Operating Income	N/A	-$2.1M-53.9%	-$1.4M-62.2%	-$848K	N/A	-$960K+13.2%	-$1.1M+12.8%	-$1.3M
Net Income	N/A	$747K+110.1%	-$7.4M+11.3%	-$8.4M	N/A	-$3.0M-107.2%	-$1.5M-106.3%	$23.4M
EPS (Diluted)	-$0.36-111.8%	-$0.17+86.3%	-$1.24-0.8%	-$1.23-180.9%	$1.52+445.5%	-$0.44	-$0.39	$1.90

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

PMCB Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

PMCB quarterly balance sheet

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Total Assets	$46.8M-15.3%	$55.2M-7.9%	$59.9M-18.3%	$73.3M-19.1%	$90.6M+1124.0%	$7.4M+20.1%	$6.2M+6.6%	$5.8M-9.8%	$6.4M-26.0%	$8.7M+21.0%	$7.2M-23.0%	$9.3M-0.2%	$9.3M+223.8%	$2.9M+37.8%	$2.1M
Current Assets	$37.4M+67.2%	$22.4M-55.6%	$50.4M-26.0%	$68.1M-20.3%	$85.5M+3657.6%	$2.3M+119.3%	$1.0M+58.8%	$653K-49.1%	$1.3M-63.7%	$3.5M+74.2%	$2.0M-51.3%	$4.2M-0.4%	$4.2M+126.5%	$1.8M+74.6%	$1.1M
Cash & Equivalents	$18.6M+22.6%	$15.2M-69.8%	$50.2M-26.2%	$68.0M-20.3%	$85.4M+3778.1%	$2.2M+146.1%	$895K+73.7%	$515K-51.4%	$1.1M-69.4%	$3.5M+80.4%	$1.9M-28.9%	$2.7M-25.3%	$3.6M+1714.6%	$199K+1167.6%	$16K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$7K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$3K
Total Liabilities	$11.8M+259.2%	$3.3M-83.9%	$20.4M+3376.0%	$587K-16.7%	$704K-2.8%	$725K-32.7%	$1.1M+45.1%	$743K+15.3%	$644K+11.0%	$580K-9.0%	$638K-58.1%	$1.5M+306.9%	$374K-91.5%	$4.4M+0.3%	$4.4M
Current Liabilities	$826K-71.6%	$2.9M-60.7%	$7.4M+1165.2%	$587K-16.7%	$704K-2.8%	$725K-29.7%	$1.0M+38.8%	$743K+15.3%	$644K+11.0%	$580K-9.0%	$638K-58.1%	$1.5M+306.9%	$374K-90.2%	$3.8M+0.3%	$3.8M
Total Equity	$33.3M-35.8%	$51.9M+87.7%	$27.6M-62.0%	$72.7M-19.2%	$89.9M+1246.2%	$6.7M+31.3%	$5.1M+1.0%	$5.0M-12.6%	$5.8M-28.7%	$8.1M+24.0%	$6.5M-16.1%	$7.8M-13.0%	$8.9M+695.6%	-$1.5M+34.1%	-$2.3M
Retained Earnings	-$104.4M-22.9%	-$85.0M+26.5%	-$115.6M+0.3%	-$116.0M-3.9%	-$111.6M-3.9%	-$107.4M-3.4%	-$103.9M-3.8%	-$100.0M-4.2%	-$96.0M-7.7%	-$89.1M-5.2%	-$84.7M-7.7%	-$78.6M-14.5%	-$68.7M-65.8%	-$41.4M-4.0%	-$39.8M

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Total Assets	$46.8M-16.3%	$55.9M-0.2%	$56.0M+24.1%	$45.1M-18.2%	$55.2M+25.9%	$43.8M-20.5%	$55.1M-21.5%	$70.2M
Current Assets	$37.4M+80.8%	$20.7M-10.1%	$23.0M+20.5%	$19.1M-14.6%	$22.4M+31.9%	$17.0M-20.5%	$21.3M-35.1%	$32.9M
Cash & Equivalents	$18.6M-7.7%	$20.2M+30.9%	$15.4M+16.9%	$13.2M-13.1%	$15.2M-7.4%	$16.4M-21.4%	$20.8M-36.1%	$32.6M
Total Liabilities	$11.8M-28.5%	$16.5M-15.2%	$19.4M+1178.7%	$1.5M-53.7%	$3.3M-8.4%	$3.6M-69.3%	$11.6M-32.1%	$17.2M
Current Liabilities	$826K-50.8%	$1.7M+6.4%	$1.6M+48.7%	$1.1M-63.6%	$2.9M+144.0%	$1.2M-75.0%	$4.8M-36.1%	$7.5M
Total Equity	$33.3M-12.6%	$38.1M+8.2%	$35.2M-19.2%	$43.6M-16.0%	$51.9M+28.9%	$40.3M-7.4%	$43.5M-8.9%	$47.7M
Retained Earnings	-$104.4M-4.4%	-$100.0M+0.7%	-$100.7M-7.9%	-$93.3M-9.8%	-$85.0M+12.1%	-$96.7M-3.3%	-$93.7M-1.6%	-$92.2M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

PMCB Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

PMCB quarterly cash flow statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Operating Cash Flow	-$5.2M-73.0%	-$3.0M-38.4%	-$2.2M+43.3%	-$3.8M+7.9%	-$4.1M-23.6%	-$3.3M-42.4%	-$2.3M+18.7%	-$2.9M+43.3%	-$5.1M-52.1%	-$3.3M+23.2%	-$4.3M+4.7%	-$4.6M-193.3%	-$1.6M-298.2%	-$390K-50.6%	-$259K
Investing Cash Flow	$2.0M+128.6%	-$7.0M-40.0%	-$5.0M	$0	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A	-$647K+25.8%	-$872K
Financing Cash Flow	$6.6M+126.3%	-$25.0M-133.7%	-$10.7M+21.0%	-$13.6M-115.5%	$87.3M+1783.0%	$4.6M+70.1%	$2.7M+16.4%	$2.3M-12.6%	$2.7M-45.1%	$4.9M	N/A	N/A	N/A	$1.2M+12.0%	$1.1M
Share Buybacks	$402K-84.2%	$2.5M-91.0%	$28.2M+107.9%	$13.6M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Operating Cash Flow	-$1.4M-77.0%	-$787K+19.7%	-$980K+50.9%	-$2.0M-91.7%	-$1.0M-104.0%	-$510K+51.7%	-$1.1M-182.5%	-$373K
Investing Cash Flow	$0-100.0%	$5.0M+266.7%	-$3.0M	$0	$0	$0	$0+100.0%	-$7.0M
Financing Cash Flow	-$170K-131.2%	$544K-91.2%	$6.2M	$0+100.0%	-$172K+95.7%	-$3.9M+63.3%	-$10.7M-5.6%	-$10.2M
Share Buybacks	$0-100.0%	$402K	$0	$0-100.0%	$172K-23.8%	$225K-84.0%	$1.4M+89.1%	$742K

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.

PMCB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

PMCB quarterly financial ratios

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	20.9%-50.0pp	70.9%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-13851.7%	-2928.5%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-13142.3%	-2853.6%
Return on Equity	-58.3%-117.4pp	59.1%+57.9pp	1.2%+7.2pp	-5.9%-1.2pp	-4.7%+48.5pp	-53.2%+22.0pp	-75.2%+5.5pp	-80.7%+37.7pp	-118.4%-63.4pp	-54.9%+38.0pp	-93.0%+34.7pp	-127.6%+177.1pp	-304.8%	N/A	N/A
Return on Assets	-41.5%-97.1pp	55.6%+55.0pp	0.6%+6.5pp	-5.9%-1.2pp	-4.7%+43.3pp	-48.0%+14.1pp	-62.1%+8.3pp	-70.3%+36.1pp	-106.5%-55.2pp	-51.3%+33.4pp	-84.7%+22.1pp	-106.8%+185.8pp	-292.6%-237.0pp	-55.5%+35.4pp	-91.0%
Current Ratio	45.28+37.6x	7.68+0.9x	6.80-109.4x	116.18-5.2x	121.38+118.2x	3.14+2.1x	1.01+0.1x	0.88-1.1x	1.99-4.1x	6.10+2.9x	3.19+0.4x	2.74-8.5x	11.20+10.7x	0.49+0.2x	0.28
Debt-to-Equity	0.35+0.3x	0.06-0.7x	0.74+0.7x	0.010.0x	0.01-0.1x	0.11-0.1x	0.21+0.1x	0.150.0x	0.110.0x	0.070.0x	0.10-0.1x	0.20+0.2x	0.04	N/A	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Return on Equity	N/A	2.0%+23.0pp	-21.1%-1.9pp	-19.2%	N/A	-7.6%-4.2pp	-3.4%-52.5pp	49.1%
Return on Assets	N/A	1.3%+14.6pp	-13.3%+5.3pp	-18.5%	N/A	-7.0%-4.3pp	-2.7%-36.0pp	33.4%
Current Ratio	45.28+32.9x	12.33-2.3x	14.60-3.4x	18.01+10.3x	7.68-6.5x	14.20+9.7x	4.47+0.1x	4.40
Debt-to-Equity	0.35-0.1x	0.43-0.1x	0.55+0.5x	0.030.0x	0.060.0x	0.09-0.2x	0.27-0.1x	0.36

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Nucana NCNA

$6.1M

TNF Pharmaceuticals TNFA

$9.6M

Hcw Biologics Inc. HCWB

$5.8M

Aim Immunotech AIM

$7.6M

CERo Therapeutics CERO

$177K

Where Pharmacyte Biotech Inc Ranks

Frequently Asked Questions

What is Pharmacyte Biotech Inc's annual revenue?

Pharmacyte Biotech Inc (PMCB) reported $0 in total revenue for fiscal year 2026. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Pharmacyte Biotech Inc profitable?

No, Pharmacyte Biotech Inc (PMCB) reported a net income of -$19.4M in fiscal year 2026.

What is Pharmacyte Biotech Inc's return on equity (ROE)?

Pharmacyte Biotech Inc (PMCB) has a return on equity of -58.3% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Pharmacyte Biotech Inc's operating cash flow?

Pharmacyte Biotech Inc (PMCB) recorded an outflow of $5.2M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are Pharmacyte Biotech Inc's total assets?

Pharmacyte Biotech Inc (PMCB) had $46.8M in total assets as of fiscal year 2026, including both current and long-term assets.

How much does Pharmacyte Biotech Inc spend on research and development?

Pharmacyte Biotech Inc (PMCB) invested $391K in research and development during fiscal year 2026.

Does Pharmacyte Biotech Inc buy back shares?

Yes, Pharmacyte Biotech Inc (PMCB) spent $402K on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does Pharmacyte Biotech Inc have outstanding?

Pharmacyte Biotech Inc (PMCB) had 11M shares outstanding as of fiscal year 2026.

What is Pharmacyte Biotech Inc's current ratio?

Pharmacyte Biotech Inc (PMCB) had a current ratio of 45.28 as of fiscal year 2026, which is generally considered healthy.

What is Pharmacyte Biotech Inc's debt-to-equity ratio?

Pharmacyte Biotech Inc (PMCB) had a debt-to-equity ratio of 0.35 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pharmacyte Biotech Inc's return on assets (ROA)?

Pharmacyte Biotech Inc (PMCB) had a return on assets of -41.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

How does Pharmacyte Biotech Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, Pharmacyte Biotech Inc (PMCB) held $18.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.2M over that year. Dividing the one by the other, the reported balance equals about 44 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Pharmacyte Biotech Inc's Altman Z-Score?

Pharmacyte Biotech Inc (PMCB) has an Altman Z-Score of -2.39, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Pharmacyte Biotech Inc's Piotroski F-Score?

Pharmacyte Biotech Inc (PMCB) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pharmacyte Biotech Inc's earnings high quality?

Pharmacyte Biotech Inc (PMCB) reported a net loss of $19.4M while operations used $5.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.